盐酸美法仑(Melphalan hydrochloride) - 药物靶点：DNA_在研适应症：葡萄膜黑色素瘤，急性淋巴细胞白血病，急性髓性白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Captisol-Enabled melphalan、CE melphalan、CE-Melphalan HCl

+ [10]

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)、DNA烷化剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [6]

在研适应症

葡萄膜黑色素瘤急性淋巴细胞白血病急性髓性白血病+ [8]

非在研适应症

免疫球蛋白轻链淀粉样变性系统性淀粉样变性

原研机构

Apotex, Inc.

在研机构

Adienne SRL

Acrotech Biopharma LLC初创企业

Apotex, Inc.

+ [3]

非在研机构

Spectrum Pharmaceuticals, Inc.

最高研发阶段批准上市

首次获批日期

加拿大 (1963-09-26),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构

分子式C13H19Cl3N2O2

InChIKeyOUUYBRCCFUEMLH-YDALLXLXSA-N

CAS号3223-07-2

关联

28

项与盐酸美法仑相关的临床试验

NCT05013437 / Withdrawn早期临床1期IIT

A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients

The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in transplant to study sensitivity of the tumor to melphalan. Melphalan is approved by the U.S. Food and Drug Administration (FDA) for transplant for MM patients.

开始日期2023-09-01

申办/合作机构

The Case Comprehensive Cancer Center

NCT05438394 / Recruiting临床1期IIT

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for Injection in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

This study is an investigator-initiated clinical study to evaluate the safety and tolerability of melphalan hydrochloride for injection in patients with relapsed or relapsed refractory multiple myeloma. Using the "3 + 3" dose escalation principle, 3-6 subjects per dose were enrolled, depending on the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group.

开始日期2022-10-13

申办/合作机构

北京大学人民医院

[+1]

NCT05022901 / Active, not recruiting临床3期

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.
This study will evaluate the safety and effects of the treatment.

开始日期2022-06-10

申办/合作机构

Delcath Systems, Inc.

100 项与盐酸美法仑相关的临床结果

登录后查看更多信息

100 项与盐酸美法仑相关的转化医学

登录后查看更多信息

100 项与盐酸美法仑相关的专利（医药）

登录后查看更多信息

1,122

项与盐酸美法仑相关的文献（医药）

2024-06-01·Journal of neurointerventional surgery

Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma

Article

作者: Srinivasan, Visish M ; Naik, Anant ; Jubran, Jubran H ; Li, Amanda ; Luong, Hanna ; Ramasubramanian, Aparna ; Feldman, Michael J ; Albuquerque, Felipe C ; Scherschinski, Lea ; Abruzzo, Todd A

Background:

Melphalan, which is poorly soluble at room temperature, is widely used for the treatment of retinoblastoma by selective ophthalmic artery infusion. Evomela, a propylene glycol-free formulation of melphalan with improved solubility and stability, has recently been used as an alternative.To compare the safety and efficacy of Evomela with standard-formulation melphalan (SFM) in the treatment of retinoblastoma by selective ophthalmic artery infusion.

Methods:

We performed a retrospective case–control study of patients with retinoblastoma undergoing selective ophthalmic artery infusion with SFM or Evomela at a single institution. Cycle-specific percent tumor regression (CSPTR) was estimated by comparing photos obtained during pretreatment examination under anesthesia (EUA) with those obtained during post-treatment EUA 3–4 weeks later. CSPTR, ocular salvage rates, complication rates, operation times (unadjusted and adjusted for difficulty of ophthalmic artery catheterization), and intraprocedural dose expiration rates were compared between Evomela- and SFM-treated groups. Univariate and multivariate analyses were performed.

Results:

Ninety-seven operations (melphalan: 45; Evomela: 52) for 23 patients with 27 retinoblastomas were studied. The ocular salvage rate was 79% in the SFM-treated group and 69% in the Evomela-treated group. Multivariate regression controlling for tumor grade, patient age, and treatment history revealed no significant differences in ocular salvage rate, CSPTR, complication rates, or operation times. Although the dose expiration rate was higher for the SFM-treated group, the difference was not statistically significant. Notably, there were no ocular or cerebral ischemic complications.

Conclusion:

Evomela has non-inferior safety and efficacy relative to SFM when used for the treatment of retinoblastoma by selective ophthalmic artery infusion.

2024-05-01·Ophthalmology and therapy

Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment

Article

作者: Enríquez-de-Salamanca, Amalia ; González-García, María J ; García-Vázquez, Carmen ; Calonge, Margarita ; Valencia-Nieto, Laura ; Fernández, Itziar ; Pinto-Fraga, José ; Blanco-Vázquez, Marta ; López-Miguel, Alberto

INTRODUCTION:

To evaluate the short-term efficacy of cyclosporine A (CsA)-0.1% cationic emulsion (CE) in patients with dry eye disease (DED) and mitigation of the inflammatory flares triggered by desiccating stress environments.

METHODS:

A single-center non-randomized clinical trial was performed at a tertiary care setting. Twenty patients with DED treated with CsA 0.1% CE were exposed to a normal controlled environment (NCE) (23 °C, 50% relative humidity) and an adverse controlled environment (ACE) (23 °C, 10% relative humidity, 0.43 m/s localized airflow) during baseline and the 1- and 3-month visits. Patients underwent the following evaluations: conjunctival hyperemia and staining, corneal fluorescein staining (CFS) using the Oxford and Cornea and Contact Lens Research Unit (CCLRU) scale, meibomian gland (MG) secretion quality, Dry Eye Questionnaire-5, Symptom Assessment in Dry Eye (SANDE II), and Change in Dry Eye Symptoms Questionnaire. Multivariate models were adjusted for statistical analysis.

RESULTS:

Nineteen women and one man (mean age, 58.9 ± 12.3 years) completed the study. All symptom questionnaires, CFS, conjunctival hyperemia and staining, and MG secretion quality improved (p ≤ 0.003) with 1 month of treatment; improvements were maintained after 3 months (p ≤ 0.02), except for SANDE II (p ≥ 0.07). The CFS worsening (total CCLRU) after baseline ACE exposure (from 8.6 to 10.1) was higher, although not significant (p = 0.64), compared with 1 month (from 5.4 to 5.8) and 3 months (from 5.0 to 5.9) after treatment.

CONCLUSION:

Topical CsA-0.1% CE improved DED signs and symptoms after 1 month of treatment under controlled environmental conditions. Future studies should confirm the benefit of CsA-0.1% CE in desiccating stress environments.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT04492878.

2024-05-01·Food chemistry

Identification and molecular binding mechanism of novel pancreatic lipase and cholesterol esterase inhibitory peptides from heat-treated adzuki bean protein hydrolysates

Article

作者: Jiang, Yuanrong ; Fan, Yimeng ; Gu, Jie ; Zhao, Qingyu ; Zhao, Liangxing ; Hao, Zhihui ; Shen, Qun ; Zhu, Yiqing ; Xue, Yong

Heat-treated adzuki bean protein hydrolysates exhibit lipid-reducing properties; however, few studies have reported pancreatic lipase (PL) and cholesterol esterase (CE) inhibitory effects and elucidated the underlying mechanisms. In this study, we accomplished the identification of antiobesity peptides through peptide sequencing, virtual screening, and in vitro experiments. Furthermore, the mechanisms were investigated via molecular docking. The findings reveal that the action of pepsin and pancreatin resulted in the transformation of intact adzuki bean protein into smaller peptide fragments. The < 3 kDa fraction exhibited a high proportion of hydrophobic amino acids and displayed superior inhibitory properties for both PL and CE. Five novel antiobesity peptides (LLGGLDSSLLPH, FDTGSSFYNKPAG, IWVGGSGMDM, YLQGFGKNIL, and IFNNDPNNHP) were identified as PL and CE inhibitors. Particularly, IFNNDPNNHP exhibited the most robust biological activity. These peptides exerted their inhibitory action on PL and CE by occupying catalytic or substrate-binding sites through hydrogen bonds, hydrophobic interactions, salt bridges, and π-π stacking.

145

项与盐酸美法仑相关的新闻（医药）

2024-11-01

·Business Wire

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--( BUSINESS WIRE )--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: Stephens Biotechnology Virtual Fireside Chats Date: Wednesday, November 13, 2024 Fireside Chat Time: 9:30 am Eastern Time Location: Virtual 15th Annual Craig-Hallum Alpha Select Conference Date: Tuesday, November 19, 2024 1x1 Meetings Location: New York, NY About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to surgically isolate the liver while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

上市批准

2024-10-31

·摩熵医药

2024国谈收官！162个品种谈判，美法仑等多款重磅潜力品种亮相，四大明星CAT-T再次落榜……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。经过4天的激烈谈判，2024年国谈于10月30日正式收官。本次谈判共有162个品种参与，涵盖了医保目录外的117种和目录内的45种，谈判涉及的品种涵盖了糖尿病、高血压、抗感染等民众常用药品，以及肿瘤药物和罕见病治疗药物等多个领域。今年的162个品种通过率仅为41.3%，这一比例创下历年新低。此外，2024年的国谈对实验与临床数据的真实性提出了更高要求。而本次谈判中，有多款肿瘤高值创新药和罕见病新药首次纳入谈判范围，如康方生物的卡度尼利单抗、依沃西单抗均是首次出现在初审名单中。据NMPA官网批件信息显示，仅2024年上半年，就有44款新药在中国首次获批上市，其中1类创新药有23款，而首次开“谈”的创新药中涵盖了肿瘤、代谢、神经、罕见病等多个疾病领域。非独家品种竞价激烈，多款潜力品种亮相在谈判过程中，非独家药品企业竞价尤为激烈。首日谈判品种涵盖消化、抗病毒、麻醉镇痛、降压等领域，企业涉及恒瑞、默沙东等参与，产品包含阿泰特韦片/利托那韦片、玛巴洛沙韦片等。次日聚焦单克隆抗体药物和肿瘤药物等创新药物，涵盖抗肿瘤、降糖等慢病药物重磅开谈，产品涉及海思科的考格列汀片和江苏恒瑞的脯氨酸加格列净片等。随着谈判的深入，第三天焦点逐渐转向中药和替尼类药物，此次谈判中成药品种创近年来新高，约为20多个，含多款1.1类新药亮相。最后一天，非独家药品竞价战打响，帕拉米韦注射液等流感治疗重药成为竞逐焦点，帕拉米韦注射液是一种流感病毒神经氨酸酶抑制剂，可选择性地抑制人甲型和乙型流感病毒的神经氨酸酶活性，是甲乙型流感治疗的重要药物。据摩熵医药数据库显示，帕拉米韦相关剂型品种在2023年全国院内市场的销售额超6亿元，同比增长达93.10% 截图来源：摩熵医药（原药融云）全国医院销售数据库除了大规模竞价谈判外，还有多款潜力巨大的药品单独亮相谈判桌。如西安力邦的注射用盐酸美法仑、杭州中美华东制药的他克莫司颗粒，以及石药集团欧意药业的哌柏西利片，其中注射用盐酸美法仑适用于口服治疗不合适的多发性骨髓瘤患者的姑息治疗，据摩熵医药数据库显示，该品种在2023年全国院内市场的销售额超1亿元，同比增长达30.76%，市场潜力可期。此外，原研药企在全国医院市场中占据了高达95.24%的份额。截图来源：摩熵医药（原药融云）全国医院销售数据库四大明星CAT-T再次落榜，多次无缘医保此次2024年的国家医保谈判中，CAR-T药物作为“百万抗癌药”备受瞩目。2024年8月27日，据国家医保局发布关于2024年国家基本医疗保险、工伤保险和生育保险药品目录调整形式审查通过药品名单的公告。截图来源：国家医疗保障局此次公告中，有四款明星CAR-T药物成功通过形式审查，涉及上海药明巨诺生物科技的瑞基奥仑赛注射液、科济药业的泽沃基奥仑赛注射液、合源生物的纳基奥仑赛注射液以及复星凯特生物科技的阿基仑赛注射液，其中阿基仑赛注射液于2021年6月在国内首次上市，据摩熵医药数据库统计，该药物在2023年的全球销售额已超过14亿美元。截图来源：摩熵医药（原药融云）全球药物研发数据库由于价格昂贵，接近或超过百万元，CAR-T药物的可及性受限，且此前三次均因“50万不谈，30万不进”的规则未进入谈判。此次2024国谈，“百万抗癌药”CAR-T药物再次落榜，这已是其第4次无缘医保。小结尽管CAR-T药物等高价药品未能进入医保目录，但本次国谈的成果仍然丰硕。通过谈判纳入的药品已惠及8亿参保患者，累计减负超8000亿元，医保基金支付超3400亿元。此外，新版药品目录将于2025年1月1日起实施，更多优质药品将纳入医保范围，为患者带来更多福音。本次国谈虽已落幕，最终结果如何，仍待后续公布。同时，我们也期待在未来的谈判中，能够有更多创新药和高价药品被纳入医保目录，进一步扩大患者的受益范围。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

上市批准医药出海一致性评价

2024-10-30

·赛柏蓝

2024年国谈最后一天现场直击！石药、齐鲁、雅培等现身，涉降糖、肿瘤、抗菌、抗病毒药...

现场 | 颜色文字 | 凯西 2024年国家医保谈判终于来到了最后一天！有的企业谈判代表拖着行李箱出现在全国人大会议中心。赛柏蓝摄于现场北京相比于前几天有所降温（最高温度18度，最低温度6度）。 10月30日早上7点半左右，赛柏蓝现场观察发现，全国人大会议中心门外等待的谈判代表相较于前几天有所减少。随着工作人员的点名，石药集团欧意药业、江苏德源、杭州中美华东制药江东有限公司、齐鲁、江苏联环药业、正大天晴、河北天成药业、海南通用三洋药业、雅培贸易、西安力邦制药等企业的谈判代表陆续入场。目前谈判代表仍在进场中，进场的谈判代表人数在1-3人不等。据悉，今天上午谈判/竞价的产品包括抗排异药、降糖药、抗肿瘤药、抗菌药、抗病毒药等，如帕拉米韦注射液、注射用盐酸头孢吡肟/氯化钠注射液、注射用盐酸美法伦、二甲双胍恩格列净片等。随着今天谈判的顺利结束，2024年国家医保目录发布进入倒计时。根据国家医保局10月24日消息，预计11月份公布调整结果，新版药品目录将于2025年1月1日起实施。 END 内容沟通：郑瑶（13810174402）

一致性评价

100 项与盐酸美法仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08173	盐酸美法仑	L01AA03	DB01042

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
葡萄膜黑色素瘤	美国	Delcath Systems, Inc.	2023-08-14
急性淋巴细胞白血病	欧盟	Adienne SRL	2020-11-16
急性淋巴细胞白血病	冰岛	Adienne SRL	2020-11-16
急性淋巴细胞白血病	列支敦士登	Adienne SRL	2020-11-16
急性淋巴细胞白血病	挪威	Adienne SRL	2020-11-16
急性髓性白血病	欧盟	Adienne SRL	2020-11-16
急性髓性白血病	冰岛	Adienne SRL	2020-11-16
急性髓性白血病	列支敦士登	Adienne SRL	2020-11-16
急性髓性白血病	挪威	Adienne SRL	2020-11-16
霍奇金淋巴瘤	欧盟	Adienne SRL	2020-11-16
霍奇金淋巴瘤	冰岛	Adienne SRL	2020-11-16
霍奇金淋巴瘤	列支敦士登	Adienne SRL	2020-11-16
霍奇金淋巴瘤	挪威	Adienne SRL	2020-11-16
乳腺腺癌	欧盟	Adienne SRL	2020-11-16
乳腺腺癌	冰岛	Adienne SRL	2020-11-16
乳腺腺癌	列支敦士登	Adienne SRL	2020-11-16
乳腺腺癌	挪威	Adienne SRL	2020-11-16
神经母细胞瘤	欧盟	Adienne SRL	2020-11-16
神经母细胞瘤	冰岛	Adienne SRL	2020-11-16
神经母细胞瘤	列支敦士登	Adienne SRL	2020-11-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
眼部黑色素瘤	申请上市	美国	Delcath Systems, Inc.	2023-03-27
免疫球蛋白轻链淀粉样变性	临床2期	美国	Spectrum Pharmaceuticals, Inc.	2018-01-08
系统性淀粉样变性	临床2期	美国	Spectrum Pharmaceuticals, Inc.	2018-01-08
浆细胞骨髓瘤难治	临床1期	中国	CASI Pharmaceuticals, Inc.	2022-10-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


BusinessWire 人工标引	N/A	葡萄膜黑色素瘤二线 \| 一线	30	HEPZATO KIT as first-line therapy	鏇齋窪蓋壓築窪網壓餘(齋淵夢範願願襯襯願夢) = 積夢獵願範遞觸淵窪觸壓艱願簾窪壓製憲鬱膚 (衊鏇願顧顧鹽衊襯簾範 ) 更多	积极	2024-08-27
				HEPZATO KIT as second-line therapy	鏇齋窪蓋壓築窪網壓餘(齋淵夢範願願襯襯願夢) = 鬱淵築夢壓積選遞餘鹹壓艱願簾窪壓製憲鬱膚 (衊鏇願顧顧鹽衊襯簾範 ) 更多
NCT03417284 (EHA2024) 人工标引	临床1/2期	多发性骨髓瘤一线	60	EVOMELA (short infusion)	窪願窪網鏇鏇構積衊獵(構構醖壓窪簾膚獵襯窪) = 鬱遞餘觸艱齋壓鬱廠醖遞築鹹憲繭網構壓觸襯 (構遞繭醖簾遞鹹鑰鬱廠 ) 更多	积极	2024-05-14
				EVOMELA (extend infusion)	窪願窪網鏇鏇構積衊獵(構構醖壓窪簾膚獵襯窪) = 夢艱獵構夢壓壓積壓夢遞築鹹憲繭網構壓觸襯 (構遞繭醖簾遞鹹鑰鬱廠 ) 更多
Tandem Meetings ASTCT and CIBMTR2024 人工标引	N/A	多发性骨髓瘤一线	60	Evomela (Short Infusion (S-IV))	艱鬱願繭醖淵積鏇願觸(蓋蓋壓糧簾夢鏇餘齋糧) = 醖構網糧齋襯鏇鬱鑰窪醖餘膚襯齋願餘鹽餘鏇 (膚鑰艱製觸糧壓鬱窪獵 ) 更多	积极	2024-02-01
				Evomela (Long Infusion (L-IV))	艱鬱願繭醖淵積鏇願觸(蓋蓋壓糧簾夢鏇餘齋糧) = 壓網糧顧築衊繭鹽觸鑰醖餘膚襯齋願餘鹽餘鏇 (膚鑰艱製觸糧壓鬱窪獵 ) 更多
Tandem Meetings ASTCT and CIBMTR2024	临床2期	血液肿瘤	42	Fludarabine (Flu) 40mg/m2 x4, Mel140mg/m2, TBI200cGy	艱鹽齋廠構鹹廠獵憲鏇(鬱壓遞壓餘製膚衊鹽淵) = 願積衊繭獵製築製鏇獵築膚構齋夢廠鑰鹽顧窪 (簾鬱網獵築繭遞鬱艱築 ) 更多	积极	2024-02-01
				FluMel100TBI400	鹽鹹觸廠醖繭構淵齋構(選衊簾窪醖糧範憲範襯) = 選築襯鏇簾積齋淵範網淵齋蓋鑰鹽餘製選襯構 (糧襯淵鏇壓築遞鏇壓願 )
ASH2023	临床1/2期	多发性骨髓瘤	60	Evomela (Short infusion)	夢壓願遞醖製築蓋醖蓋(廠獵積襯餘構鏇廠鹹簾): HR = 9.5 (95% CI, 1 ~ 91.2), P-Value = 0.022	-	2023-12-11
				Evomela (Extended infusion)
FDA 人工标引	N/A	多发性骨髓瘤	295	Melphalan hydrochloride (Oral)	築蓋齋製壓艱淵築鹽廠(衊構鹽鹽醖網蓋繭積衊) = 構憲壓顧廠鏇簾鏇憲積憲憲憲繭蓋積壓鏇蓋衊 (觸選窪獵鹹鏇餘廠蓋範 ) 更多	积极	2023-08-18
				Melphalan hydrochloride + Intravenous	築蓋齋製壓艱淵築鹽廠(衊構鹽鹽醖網蓋繭積衊) = 選糧醖築淵壓鹽獵範淵憲憲憲繭蓋積壓鏇蓋衊 (觸選窪獵鹹鏇餘廠蓋範 ) 更多
NCT02994784 (CTgov)	临床2期	免疫球蛋白轻链淀粉样变性 \| 系统性淀粉样变性	27	Propylene Glycol-Free Melphalan Hydrochloride	觸觸窪構壓襯壓網醖膚(齋餘觸窪壓膚鹽觸顧簾) = 膚壓憲襯壓觸製窪鹽願鑰範製鏇齋廠壓餘構齋 (鏇憲膚願積鏇鑰廠艱蓋, 獵憲膚積積遞築憲簾選 ~ 範齋鑰鏇繭製觸鹽繭憲) 更多	-	2023-05-24
Tandem Meetings ASTCT and CIBMTR2023	N/A	多发性骨髓瘤 creatinine clearance	42	Propylene Glycol-Free Melphalan (Evomela) (Short infusion schedule)	鹹築餘鹽獵獵艱壓憲鏇(襯願範膚膚壓遞齋夢鬱) = 齋艱觸醖衊壓齋遞鏇衊網鏇選鬱壓鬱醖鑰齋網 (夢鏇糧願獵願願簾膚製, 3962) 更多	-	2023-02-01
				Propylene Glycol-Free Melphalan (Evomela) (Long infusion schedule)	鹹築餘鹽獵獵艱壓憲鏇(襯願範膚膚壓遞齋夢鬱) = 選構艱膚顧獵餘範觸餘網鏇選鬱壓鬱醖鑰齋網 (夢鏇糧願獵願願簾膚製, 4517) 更多
P125 (EBMT2021)	N/A	巩固	59	High-dose melphalan	顧鹹膚簾餘夢構襯網製(鑰糧鑰築夢夢鏇築鹹廠) = 顧網選壓鬱夢鏇糧鏇壓憲餘積膚願選構衊廠窪 (淵鏇衊鹽鏇鹹醖鹹蓋衊, 59 ~ 112) 更多	积极	2021-03-14
Tandem Meetings ASTCT and CIBMTR2019	N/A	多发性骨髓瘤	-	Evomela	簾襯築鹹廠獵顧蓋膚糧(淵夢蓋願鏇構鏇願夢窪) = 膚鏇網願齋積願築廠鬱衊衊觸鏇製網齋觸遞壓 (獵鏇蓋繭積遞襯遞積夢 ) 更多	-	2019-03-01
				Propylene Glycol-based Melphalan Hydrochloride	簾襯築鹹廠獵顧蓋膚糧(淵夢蓋願鏇構鏇願夢窪) = 襯構鹽襯鬱餘築齋鬱夢衊衊觸鏇製網齋觸遞壓 (獵鏇蓋繭積遞襯遞積夢 ) 更多